Is there a role for early GLP-1 therapy for weight loss in patients with early-stage ADPKD and obesity, given the association between obesity and the risk of progression to ESKD?

Indeed, maintaining a healthy BMI is an important evidence-based guideline in ADPKD, but no data exist for early GLP-1 therapy and early-stage ADPKD at this time. Weight loss has not yet been shown to be protective of eGFR in ADPKD, although of course, conceptually, we believe that to be true. That ...